USE1

Across TCGA pan-cancer cohorts, USE1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated USE1 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher USE1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated USE1 expression acts as an unfavorable survival marker.

BLCA and STAD are the cancer types where USE1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.051	0.600	<.001	12	view →
STAD	DFS	Median	All	0.211	0.709	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

USE1–BLCA (OS)

Open the BLCA breakdown →